Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia

Journal of Clinical Investigation

Volumn 108, Issue 9, 2001, Pages 1321-1330

  He, Li Zhen ^a   Tolentino, Thomas ^a   Grayson, Peter ^a   Zhong, Sue ^a   Warrell Jr , Raymond P ^b   Rifkind, Richard A ^a   Marks, Paul A ^a   Richon, Victoria M ^a   Pandolfi, Pier Paolo ^a,c  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; GENE PRODUCT; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ONCOPROTEIN; PROTEIN PLZF; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 17; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FUSION GENE; GENE LOCUS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TARGET ORGAN; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IN SITU NICK-END LABELING; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MODELS, CHEMICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLBUTYRATES; PROTEIN BINDING; RECEPTORS, RETINOIC ACID; REMISSION INDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035189761     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200111537     Document Type: Article

References (66)

1. Acute promyelocytic leukemia
2. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
3. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
4. Structure and origin of the acute promyelocytic leukaemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties
5. The PML/RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
6. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor
7. Characterization ofazinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia
8. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia
9. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;21) in a patient with acute promyelocytic leukemia
10. The t(15; 17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion
11. Fusion of retinoic acid receptor alpha to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia
12. The signal transducer and activator of transcription STAT5b gene is a new partner ofretinoic acid receptor alpha in acute promyelocytic-like leukemia
13. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
14. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
15. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
16. A decade of molecular biology of retinoic acid receptors
17. Molecular mechanisms ofcorepressor function
18. Avian erythroleukemia: A model for corepressor function in cancer
19. Histone acetylation in chromatin structure and transcription
20. Cellular biology and biochemistry of the retinoids
21. Retinoids in cancer therapy
22. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
23. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
24. Role of the histone deacetylase complex in acute promyelocytic leukaemia
25. Acute leukemia with promyelocytic features in PML/RARα transgenic mice
26. Effects of sodium butyrate, a new pharmacological agent, on cells in culture
27. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function
28. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
29. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
30. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
31. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
32. Initial clinical evaluation of transcription therapy for cancer: All-trans retinoic acid plus phenylbutyrate
33. Histone deacetylase inhibitors
34. Two hits are critical for promyelocytic leukemia
35. 3 treatment in transgenic models of APL unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins
36. A novel assay for apoptosis. FIVow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V
37. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
38. WAF1, a potential mediator of p53 tumor suppression
39. Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation
40. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase
41. Interpreting patterns of gene expression with selforganizing maps: Methods and application to hematopoietic differentiation
42. Unliganded thyroid hormone receptor alpha can target TATA-binding protein for transcriptional repression
43. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway
44. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia
45. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
46. Transcription therapy for cancer
47. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
48. Role for N-CoR and histone deacetylase in Sin3mediated transcriptional repression
49. Retinoblastoma protein recruits histone deacetylase to repress transcription
50. Retinoblastoma protein represses transcription by recruiting a histone deacetylase
51. Rb interacts with histone deacetylase to repress transcription
52. Rearrangements of the BCL-6 gene in diffuse large-cell non-Hodgkins lymphoma
53. Lymphocyte ontogeny: A conceptual basis for understanding neoplasia of the immune system
54. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein
55. Chromosomal translocations cause deregulated BCL-6 expression by promoter substitution in B-cell lymphoma
56. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
57. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
58. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
59. Induction ofapoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53
60. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
61. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
62. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects
63. A synthetic inhibitor ofhistone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
64. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
65. Suberoylanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
66. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent against tobacco-specific nitrosamine 4-(methylnitro-amino)-1-(3-pyridyl)-lbutanone (NNK)-induced lung tumorigenesis